- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2024–2029 · career development · K08
Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia
Emily Heikamp · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2025 · career development · K99
Dissecting the Role of Germline Genetics in RAS-Driven Cancers
Ryan Lewis Collins · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
High-throughput single-cell RNA sequencing of bacteria to uncover cell states involved in pathogenesis
Sahand Hormoz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2025 · fellowship · F32
Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma
Michael Joseph Bond · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · research · R01
Survival Data Analysis using general censoring-free incident rate
Hajime Uno · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Design of a Scalable and Sustainable PREMMplus Patient-Facing App and Implementation in Three Healthcare Settings
Sapna Syngal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors
Joanna J Arch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2030 · research · R01
Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors
Rachel Ann Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K08
Inflammatory Disease Associations in Clonal Hematopoiesis
Lachelle Dawn Weeks · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · research · R01
Enhanced radiotherapy for pediatric glioma via synthetic lethal vulnerabilities
Dipanjan Chowdhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K08
Validation and implementation of ctDNA as a clinically informative biomarkerin AYAs with sarcomas.
David Shulman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · career development · K08
Integrating pain-CBT into an mHealth analgesic support intervention for patients withchronic pain from advanced cancers
Desiree R Hilton · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K08
Identifying metabolic regulation of T cells during early childhood development
Jared H. Rowe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · cooperative agreement · U34
Distance-based Exercise to preserve Function and prevENt Disability (DEFEND)
Jennifer A. Ligibel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · research · R21
Sexual Health and Rehabilitation (SHARE): An Online Educational Intervention for Young Adult Female Cancer Survivors
Sharon L. Bober · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · research · R01
Integrative modelling of single-cell data to elucidate the genetic architecture of complex disease
Alexander Gusev · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Targeting Replication Stress and DNA Damage Response in Uterine Cancer
Panagiotis Konstantinopoulos · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · cooperative agreement · U01
Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas
Nika N Danial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
RNA-based HIV-1 chimera vaccines encoding a trimerizing host self-protein protomer linked to a viral MPER-TM segment
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Exploiting a Novel DNA Repair Defect in Ewing Sarcoma
Alan D. D'Andrea · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · career development · K99
Towards a structural understanding of transcriptional regulation by ZMYM2-KDM1A-CoREST
Franziska Wachter · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells
Eric L Smith · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2025 · career development · K99
Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity
Jiaxin Liang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · cooperative agreement · U01
Myeloma multidimensional precancer atlas
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2031 · research · R35
Mechanisms Driving the Rapid Evolution of Cancer Genomes
David S Pellman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Targeting WEE1 in uterine serous or p53-mutated uterine cancer
Joyce Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
mRNA-based chimeric membrane protein vaccination strategies directed at the MPER
Mikyung Kim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Combined ATR and P13k inhibition in uterine cancer
Panagiotis Konstantinopoulos · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Bio statistics Core
Nabihah Tayob · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
PDX Modeling Core
Joyce Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Targeting replication stress to engage DNA sensing STING pathway derived anti-tumor immunity to improve the therapeutic outcomes in uterine cancer
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Administrative Core
Ursula Anne Matulonis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Pathology Core
Geoffrey I. Shapiro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Administrative Support Core
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Structural characterization of MPER-TM immunogens
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · program · P01
Neutralizing Antibody Core
Michael Scott Seaman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · fellowship · F32
Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability.
Michelle Swift · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · research · R37
Molecular Origins and Evolution to Chemoresistance in Germ Cell Tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023 · career development · K99
Structure and Function of the SHOC2 Holophosphatase Complex in RAS-driven Cancer
Jason Kwon · Dana-Farber Cancer Institute · funded by National Institutes of Health
